Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
-
Invivyd Announces Continued Neutralizing Activity of PEMGARDA™ (pemivibart) Against Dominant SARS-CoV-2 Variant XEC
-
Tilray Brands Reports Q2 2025 Financial Results
-
Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O’Neill, Ph.D.
-
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
-
Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update
-
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
-
Nickel Sulphate Futures Now Live for Trading on Abaxx Exchange
-
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes
-
Bio-Path Holdings Provides 2025 Clinical and Operational Update
-
Lantronix Names Brent Stringham as CFO
-
Plymouth Industrial REIT Provides Activity Update for Fourth Quarter 2024
-
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025
-
U.S. Energy Corp. Announces Recent AcquisitionTargeting Industrial Gas Production
-
Gencor Announces Receipt of NYSE Regulation Notice Regarding Late Filing of the Annual Report on Form 10-K for the Year Ended September 30, 2024
-
The “Hottest” Bagel in New York is Opening Its First Boston Location
-
Walden Biosciences Highlights 2024 Accomplishments and 2025 Priorities
-
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
-
Green Thumb Industries Announces First-Of-Its-Kind Partnership with Iconic Chicago Music Venue, The Salt Shed, Introducing Retail Store RISE at Salt Shed and RYTHM Brand Activations
-
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
-
Señorita Becomes the Exclusive Hemp-Derived THC Beverage Partner for The Salt Shed, Chicago’s Premier Music Venue
-
Amplify Energy to Participate in Fireside Chat with Alliance Global Partners on January 23, 2025
-
EnviroGold Global Announces the Upsizing of Its Unit Offering to Raise Up to $4 Million in Response to Investor Interest
-
Matthews International Files Definitive Proxy Statement and Sends Letter to Shareholders
-
Perspective Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
-
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
-
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
-
Apellis Announces Keli Walbert to Join the Board of Directors
-
ConnectOne Bancorp, Inc. to Host 2024 Fourth Quarter Results Conference Call on January 30, 2025
-
Charges brought against Aspo board member in the matter concerning Ramirent Plc have been withdrawn
-
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference
-
EDAP Appoints Joshua H. Levine to Board of Directors
-
Share Buy-back programme at SP Group A/S
-
Form 8.5 (EPT/RI) - Warpaint London Plc
-
Form 8.5 (EPT/RI) - Poolbeg Pharma Plc
-
Form 8.5 (EPT/RI) - Brand Architekts Group plc
-
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
-
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potenti
-
Auction result of Treasury Bonds - RIKB 27 0415 - RIKB 35 0917
-
Net Asset Value(s)
-
C4 Launches KOL Incubation School to Empower the Next Generation of Crypto Content Creators
-
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
-
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)
-
EXEL Industries: Total number of voting rights and shares at 11.30.2024
-
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer
-
Aura Announces Q4 2024 Production Results, Achieving 2024 Guidance
-
Armada Hoffler Announces Morningstar Upgrades Outlook to Stable and Confirms BBB Credit Rating
-
Everything Blockchain Inc. Resolves Toxic Convertible Notes, Strengthening Financial Position
-
Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)
